Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in mHSPC
NCT07140900Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 3
01
Overview
Phase 1, open-label trial of xaluritamig in prostate cancer (PCa) (2 arms), sponsored by Amgen. Primary endpoints: Treatment-emergent Adverse Events at 2.5 years, Treatment-related Adverse Events at 2.5 years and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
xaluritamig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07140900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140900.